UK Spinal Muscular Atrophy Competitive Intelligence

An estimated 1,000 UK patients live with spinal muscular atrophy across all types. The UK added SMA to its national newborn screening programme in 2021, the first national NBS programme for SMA in Europe, identifying roughly 25 pre-symptomatic patients per year and routing them to one of 6 specialist centres for early treatment. NICE has recommended all three approved SMA therapies through confidential Patient Access Scheme agreements: Zolgensma (onasemnogene abeparvovec), recommended via the Highly Specialised Technology route under NICE HST15 (2021) and expanded to the pre-symptomatic population under HST24 (2023), for Type 1 and pre-symptomatic patients with 3 or fewer SMN2 copies; Spinraza (nusinersen, NICE TA588, 2019), an intrathecal ASO, for Types 1–3; and Evrysdi (risdiplam, NICE TA755, 2022), an oral SMN2 modifier increasingly preferred by families avoiding intrathecal dosing.

The NHS treatment algorithm is now type- and age-based rather than access-based: Type 1 and NBS-identified pre-symptomatic patients under 2 years route to Zolgensma; Type 2/3 patients under 18 choose between nusinersen and risdiplam; Type 2/3 adults choose between risdiplam and nusinersen. All three agents carry confidential PAS pricing, so relative NHS net cost is commercially sensitive, but Zolgensma's cost-effectiveness case for its $2.125 million WAC was only accepted under a confidential commercial arrangement negotiated through the HST15 appraisal (2021), later expanded to presymptomatic infants under HST24 (2023) — illustrating how tightly NICE's cost-effectiveness ceiling constrains one-time gene-therapy pricing even in an ultra-rare, high-unmet-need indication. Nusinersen remains the default for roughly 300 UK patients, largely Type 2/3 adults outside Zolgensma's age/weight eligibility, while risdiplam's oral dosing is winning share in community settings by reducing the intrathecal procedure burden.

Every AXLRx brief is built from primary regulatory sources (MHRA, NICE, NHS England), peer-reviewed literature, and live NHS commissioning documentation — not secondary summaries. Findings are independently verified before inclusion.

Spinal Muscular Atrophy UK CI sources: MHRA public assessment reports, NICE HST15 (2021) and HST24 (2023) for Zolgensma, NICE TA588 (2019) for Spinraza, NICE TA755 (2022) for Evrysdi, NHS England SMA commissioning policy (2023), and UK newborn screening programme SMA data (2023).